Patients that Received Dexamethasone less Afflicted with Long COVID

Patients that Received Dexamethasone less Afflicted with Long COVID

Researchers from the North Bristol NHS Trust, Academic Respiratory Unit in Bristol, UK, recently uploaded study results to the medRxiv preprint server.  The study team sought to identify if the corticosteroid dexamethasone, proven to reduce COVID-19 mortality in certain hospitalized acute COVID-19 pneumonia scenarios thanks to the RECOVERY trial, could help reduce symptoms associated with long-COVID.

The RECOVERY trial led to a material change in how acute COVD-19 was managed, and according to the study authors, saved approximately 1 million lives worldwide. 

Importantly, however, steroids have a downside, even if administered on a short-term basis. In the case of the RECOVERY trial, the benefits were constrained to patients requiring oxygen or already on a ventilator as compared to patients less severely affected—the latter could actually be harmed by the regimen. 

A Real Problem

Long-COVID, also known as post-COVID-19 syndrome, post-acute sequelae of COVID-19 (PASC), or chronic COVID syndrome (CSS) is characterized by long-term sequelae appearing or persisting well after the preliminary infection period associated with SARS-CoV-2. This condition may impact every...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee